Management

George O. Elston

Chief Executive Officer

During his over 25 years as a life sciences leader, executive and board member, George O. Elston has established a strong track record of building, leading and growing businesses and advancing products through clinical development and partnering.

Mr. Elston joined 2X Oncology in April 2017 as CEO and serves on the Board of Directors.  He was previously Chief Financial Officer of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), where he played a key role in negotiating and executing transformative technology and financing transactions for the women’s health therapeutics developer.

Prior to Juniper, Mr. Elston was Senior Vice President and CFO of KBI Biopharma, a biopharmaceutical CDMO. Previously, Mr. Elston served as a senior executive at Optherion, Inc., a biopharmaceutical company developing biologic drugs for the treatment of ophthalmic and autoimmune diseases, and Elusys Therapeutics, a biopharmaceutical company developing antibody-based therapies for life threatening infectious diseases. Additionally, Mr. Elston was the founder and managing partner at Chatham Street Partners, which provided strategic and CFO advisory services to the executive management and boards of life science companies.

Mr. Elston is a member of the board of directors of the Deutsche Bank DBX Trust and was previously a director of Celldex Therapeutics, Inc. (Nasdaq: CLDX).  He has a B.B.A in Public Accounting from Pace University and is a Certified Public Accountant.

Marie Foegh, M.D., DrSc

Chief Medical Officer

Dr. Marie Foegh has over 25 years of commercial leadership experience in women’s health preceded by strong academic credentials. Throughout her career, Dr. Foegh has successfully developed and achieved regulatory approval of more than ten novel drug indications. She has strong experience working with the FDA as well as consumer advocacy groups.

Dr. Foegh joined 2X Oncology in January 2017, and concurrently served as both CMO and CEO until April 2017.  Prior roles in women’s health include Chief Medical Officer and VP of Clinical Research & Development at Agile Therapeutics, a women’s health specialty pharmaceutical company; Vice President R&D, Medical Affairs, Strategy and Development, Female Health Care at Bayer Pharmaceuticals, USA; and Medical Director Women’s Health at Solvay.  Dr. Foegh also co-founded and was Chief Medical Officer of Ell Imaging, a medical device company specializing in ultrasound in women’s health.

Previously, Dr. Foegh was with the IPSEN group, where during her eight-year tenure she served as President, Henri Beaufour Institute, USA, and Medical Director, IPSEN, UK and Scandinavia (1991-1996) with focus on development of small peptides for treatment of cancers and cardiovascular diseases.

Dr. Foegh is Chair of the board of directors of Injecto AS, a medical device company, and is licensed to practice medicine in U.S. (GA, MD, VA and Washington D.C.), the UK and Scandinavia.

Jarne Elleholm

Chief Financial Officer

Jarne Elleholm has more than 20 years’ experience in the life science industry with a strong record of achievements in the commercialization of drugs and medtech products, as well as in fundraising for early stage life science companies.

In the venture capital industry, Mr. Elleholm was a partner in Vækstfonden and a Managing Partner in Inventure Capital. In these roles, he worked closely with 12 life science portfolio companies as an active lead investor and board member or Chairman.

On the corporate side, Mr. Elleholm’s prior positions include CEO of biotech company Aresa A/S, where he built up the organization and completed an IPO raising more than DKK 50 million; European Vice President for Whatman International (now part of GE Healthcare); and CEO of Lundbeck Ltd. UK, where he successfully launched several pharmaceutical products.

Mr. Elleholm currently serves as Chairman of the Board of Scandinavian Micro Biodevices and of Meta-IQ. He was previously Chairman of Fluxome Sciences, FCMB, RSP Systems and Medotech, and served on the board of directors of  CytoVac, Action Pharma, Quantibact, Proxeon and Liplasome Pharma.  He holds an M. Com from Copenhagen Business School and an MBA from INSEAD.